About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The main objectives are to improve the diagnosis of immunodeficiencies and autoimmune diseases, addressing also their heterogeneity and mechanisms in close collaboration with the pediatrics, thyroid and systemic disease groups, being internationally recognized in both areas. The group participates in numerous research projects at the Vall d'Hebron Barcelona Hospital Campus that use immunological tests developed for specific projects led by the kidney transplantation, intensive care medicine, internal medicine, allergy and rheumatology groups. During the COVID pandemic the group made contributions in improving the immunogenetic and immunological risk profiles and in the evaluation of the immune response to vaccination and natural infection, collaborating with national and international networks. The group has also generated a biobank of more than 8.000 samples from patients with COVID-19 that have been incorporated into the VHIR biobank.
The group works as a coordinator of the "Focis" Center of Excellence (Federation of Clinical Immunology Societies) of Barcelona.
PMID: 35453934 Journal: Diagnostics Year: 2022 Reference: Diagnostics (Basel). 2022 Apr 1;12(4). pii: diagnostics12040886. doi: 10.3390/diagnostics12040886. Impact factor: 3.706 Publication type: Paper in international publication Authors: Gabriel-Medina, Pablo, Diaz-Troyano, Noelia, Barquin-DelPino, Raquel, Castillo-Ribelles, Laura, Esteban, Angels, Hernandez-Gonzalez, Manuel, Ferrer-Costa, Roser, Pumarola, Tomas, Rodriguez-Frias, Francisco, Klammer, Martin et al. DOI: 10.3390/diagnostics12040886
PMID: 35460231 Journal: RHEUMATOLOGY Year: 2022 Reference: Rheumatology (Oxford). 2022 Apr 23. pii: 6572805. doi: 10.1093/rheumatology/keac252. Impact factor: 7.58 Publication type: Paper in international publication Authors: Selva-O'Callaghan, Albert, Trallero-Araguas, Ernesto, Sanz-Martinez, Maria Teresa et al. DOI: 10.1093/rheumatology/keac252
PMID: 35433311 Journal: World journal of critical care medicine Year: 2022 Reference: World J Crit Care Med. 2022 Jan 9;11(1):1-21. doi: 10.5492/wjccm.v11.i1.1. eCollection 2022 Jan 9. Impact factor: 0 Publication type: Review in international publication Authors: Ruiz-Rodriguez, Juan Carlos, Ruiz-Sanmartin, Adolfo, Perez-Carrasco, Marcos, Palmada, Clara, Ribas, Vicent, Martinez-Gallo, Monica, Hernandez-Gonzalez, Manuel, Gonzalez-Lopez, Juan J, Larrosa, Nieves, Ferrer, Ricard et al. DOI: 10.5492/wjccm.v11.i1.1
PMID: 35403441 Journal: THYROID Year: 2022 Reference: Thyroid. 2022 Jun;32(6):682-693. doi: 10.1089/thy.2021.0694. Epub 2022 May 25. Impact factor: 6.568 Publication type: Paper in international publication Authors: Zafon, Carles, Alvarez de la Sierra, Daniel, Marin-Sanchez, Ana, Gomez-Brey, Aroa, Bello, Irene, Caubet, Enric, Moreno-Llorente, Pablo, Petit, Anna, Pujol-Borrell, Ricardo, Gonzalez, Oscar et al. DOI: 10.1089/thy.2021.0694
PMID: 33868243 Journal: Frontiers in Immunology Year: 2021 Reference: Front Immunol. 2021 Mar 31;12:625591. doi: 10.3389/fimmu.2021.625591. eCollection 2021. Impact factor: 7.561 Publication type: Letter whit IF Authors: Cervera, Jose Vicente, Ibanez, Mariam, Liquori, Alessandro, Franco-Jarava, Clara, Martinez-Gallo, Monica, Rodriguez-Vega, Hector, Teresa, Jaijo, Carreras, Carmen, Such, Esperanza, Zuniga, Angel et al. DOI: 10.3389/fimmu.2021.625591
PMID: 33742673 Journal: RHEUMATOLOGY Year: 2021 Reference: Rheumatology (Oxford). 2021 Dec 24;61(1):154-162. doi: 10.1093/rheumatology/keab279. Impact factor: 7.58 Publication type: Paper in international publication Authors: Bellocchi, Chiara, Callejas-Moraga, Authors' Names Eduardo Luis, Del-Castillo, Alfredo Guillen-, Perurena-Prieto, Janire, Sanz-Martinez, Maria Teresa, Fonollosa-Pla, Vicente, Lorite-Gomez, Karen, Severino, Adriana, Simeon-Aznar, Carmen P, Mahler, Michael et al. DOI: 10.1093/rheumatology/keab279
PMID: 33422078 Journal: MALARIA JOURNAL Year: 2021 Reference: Malar J. 2021 Jan 9;20(1):35. doi: 10.1186/s12936-021-03580-x. Impact factor: 2.979 Publication type: Paper in international publication Authors: Omer, Samia, Franco-Jarava, Clara, Noureldien, Ali, Omer, Mona, Abdelrahim, Mutasim, Molina, Israel, Adam, Ishag et al. DOI: 10.1186/s12936-021-03580-x
The new technology allows more sensitive detection of scleroderma patients' autoantibodies, which are related to the severity and progression of the disease.
A study from the Vall d’Hebron Campus demonstrates that the Ex Vivo C5b-9 deposition test is useful for monitoring the activity of the complement system (CS) in patients with aHUS or transplant-associated TMA.
The results show that, in some patients with mutations in the X chromosome, the healthy gene is inactivated and the mutated gene manifests itself, which favors the onset of the disease.
